The Atlantic

Readers Discuss Extreme Drug Prices—And What to Do About Them

“The public should receive a cut of any drug profits, just as any other investor might.”
Source: Bryan Woolston / Reuters

Big Pharma’s Go-To Defense of Soaring Drug Prices Doesn’t Add Up

Many pharmaceutical companies claim that exorbitant drug costs—some companies charge patients $100,000, $200,000, or even $500,000 a year—are necessary to fund expensive research projects that generate new drugs.

But “invoking high research costs to justify high drug prices,” Ezekiel J. Emanuel wrote last week, “is deceptive.” As even some pharmaceutical executives have acknowledged, he said, “there is no necessary link between a decline in drug prices and a decline in R&D.”


Too many people are focused on driving health costs down. It sounds intuitive, but it misses a bigger opportunity: making health costs most effective.

You're reading a preview, sign up to read more.

More from The Atlantic

The Atlantic5 min readPolitics
Trump’s New Campaign Slogan Is a Confession of Failure
“Transition to Greatness” is a corporate-style euphemism that tries to spin a collapse as a success.
The Atlantic7 min readPolitics
There’s No Historical Justification for One of the Most Dangerous Ideas in American Law
The Founders didn’t believe that broad delegations of legislative power violated the Constitution, but conservative originalists keep insisting otherwise.
The Atlantic5 min readSociety
We Don’t Know What’s Behind the COVID-19 Racial Disparity. And That’s a Problem.
COVID-19 is killing black Americans with horrifying precision. Black Americans get the disease at a higher rate than white people do. Retirement homes with black residents become outbreak clusters. Black people die of COVID-19 at a higher rate than w